|
The College of American Pathologists (CAP) and the American Society of Clinical Oncology (ASCO) joint guideline on testing for HER2 status in invasive breast cancer
CAP and ASCO Press Release
(PDF, 50 KB)
Comment on the guidelines
Donation Form (Word, 32 KB)
HIPAA Form (PDF, 82 KB)
Frequently asked questions about the HER2 testing guidelines
February 6, 2007: The CAP/ ASCO Guidelines Presentation has been updated by the author on 1/11/07
View presentation (PDF, 1.5 MB)
Information for patients
|
The most recent CAP Laboratory Accreditation Program requirements for HER2 testing were published in the June 15, 2009 edition of the LAP
Checklists. These new requirements continue to assure the quality of HER2 testing provided by accredited laboratories and to incorporate the CAP/ASCO HER2 testing guidelines into the CAP accreditation program.
CAP accredited laboratories performing HER2 testing by immunohistochemistry or fluorescence in situ hybridization are required to enroll and participate in CAP-accepted proficiency testing. Performance will be monitored where laboratories must receive a passing score of 90% or better on each mailing to be considered successful. Laboratories that send HER2 slides to another facility for processing/staining and have them returned for interpretation will be required to participate in PT.
|
You can meet the PT requirements as outlined in the newly adopted CAP/ASCO HER2 testing guidelines and the updated CAP accreditation checklists with CAP Surveys.
To order the appropriate program(s) for your laboratory, please call the CAP Customer Contact Center at 1-800-323-4040 option 1 #.
View Surveys (PDF, 60 KB)
|
HER2 Testing Guidelines
